Aktieanalys

InDex Pharmaceuticals: USD50m deal with Viatris - Redeye

{newsItem.title}

Redeye Publicerad: 01 Jun 2023 07:37

Redeye endorses yesterday evenings news that InDex Pharmaceuticals have entered into a USD50m licensing agreement with Viatris Japan to develop and commercialize cobitolimod in Japan. We leave our initial comments.

Länk till analysen i sin helhet: https://www.redeye.se/research/913761/index-pharmaceuticals-usd50m-deal-with-viatris?utm_source=finwire&utm_medium=RSS

Nyheter om Flerie

Läses av andra just nu

Om aktien Flerie

Senaste nytt